Tailoring FXR Modulators for Intestinal Specificity: Recent Progress and Insights.

Area of Science:

• Pharmacology
• Hepatology
• Drug Discovery

Background:

• Farnesyl X Receptor (FXR) plays a key role in bile acid synthesis and glucose/lipid metabolism.
• Clinical trials of systemic FXR modulators have revealed undesirable side effects.
• Intestinal restriction offers a strategy to mitigate systemic toxicity of FXR modulators.

Purpose of the Study:

• To review existing intestinally restricted FXR ligands.
• To analyze strategies for enhancing intestinal selectivity of FXR modulators.
• To provide insights into the development of safer FXR-targeted therapeutics.

Main Methods:

• Comprehensive literature search for intestinally restricted FXR ligands.
• Analysis of chemical and pharmacological properties of identified ligands.
• Evaluation of design strategies for achieving intestinal selectivity.

Main Results:

• Identification of various chemical classes of intestinally restricted FXR ligands.
• Characterization of key structural and physicochemical features contributing to intestinal restriction.
• Summary of approaches used to optimize FXR modulators for targeted intestinal action.

Conclusions:

• Intestinally restricted FXR modulators represent a promising therapeutic strategy.
• Targeted drug design can enhance intestinal selectivity and improve safety profiles.
• Further development in this area holds potential for treating metabolic and liver diseases.